172 related articles for article (PubMed ID: 36641051)
1. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
[TBL] [Abstract][Full Text] [Related]
2. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
4. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
[TBL] [Abstract][Full Text] [Related]
5. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
[TBL] [Abstract][Full Text] [Related]
6. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
[TBL] [Abstract][Full Text] [Related]
7. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
[TBL] [Abstract][Full Text] [Related]
8. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
[TBL] [Abstract][Full Text] [Related]
9. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
[TBL] [Abstract][Full Text] [Related]
10. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
Tang Y; Li Y; Song T
Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
[TBL] [Abstract][Full Text] [Related]
12. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 in lung transplant recipients: A multicenter study.
Saez-Giménez B; Berastegui C; Barrecheguren M; Revilla-López E; Los Arcos I; Alonso R; Aguilar M; Mora VM; Otero I; Reig JP; Quezada CA; Pérez V; Valle M; Laporta R; Deu M; Sacanell J; Bravo C; Gavalda J; Lopez-Meseguer M; Monforte V
Am J Transplant; 2021 May; 21(5):1816-1824. PubMed ID: 33089648
[TBL] [Abstract][Full Text] [Related]
15. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
Guyon J; Novion M; Fulda V; Ducint D; Molimard M; Couzi L; Kaminski H; Salvo F; Bouchet S
J Am Soc Mass Spectrom; 2022 Oct; 33(10):1975-1981. PubMed ID: 36084269
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.
Xia T; Wang Y
Am J Transplant; 2020 Sep; 20(9):2630-2631. PubMed ID: 32400965
[No Abstract] [Full Text] [Related]
18. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
Sindelar M; McCabe D; Carroll E
J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus toxicity due to enzyme inhibition from ritonavir.
Snee I; Drobina J; Mazer-Amirshahi M
Am J Emerg Med; 2023 Jul; 69():218.e5-218.e7. PubMed ID: 37173153
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.
Agarwal S; Agarwal SK
Cardiovasc Drugs Ther; 2021 Jun; 35(3):427-440. PubMed ID: 32918656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
